CD22 and lymphoma: Another anti-CD22 ADC studied in lymphoma is pinatuzumab vedotin (pina, DCDT2980S, RG-7593), containing a cleavable maleimidocaproyl-Val-Cit-PABC linker attached to the micro-tubule inhibitor MMAE with a DAR of four (Table 2) [132].